Breast implants abroad: later surgery

A breast augmentation decision extends beyond the operation and the journey home. If an implant later needs removing or replacing, the practical question becomes who can assess it, obtain the device information and arrange further care. The first operation's location is one part of that story; it cannot, on its own, describe an individual's future risk.

A study published on 21 October 2026 in Plastic and Reconstructive Surgery – Global Open examines this later stage through the Australian Breast Device Registry. It follows the record of revision surgery, rather than tracking everyone from their original breast augmentation. That distinction is essential to reading its numbers.

What appears when another operation is needed

Researchers analyzed 30,579 cosmetic breast implant removal or replacement procedures performed in Australian residents during 2016–2023. Of these, 3,577, or 11.7%, involved implants inserted overseas; 27,002 involved implants inserted in Australia. Another 5,712 procedures were excluded because insertion location was missing. These are procedure counts, not necessarily distinct people.

Within the overseas group, 73.0% of revisions were linked to complications, compared with 69.7% in the domestic group in the main results table. Rupture or deflation was recorded in 27.0% versus 24.5%, and malposition in 24.9% versus 20.5%. All these comparisons had P values below 0.001. More than one problem can be recorded, so the categories should not be added together.

The picture is not uniformly worse in one group. Capsular contracture—tightening of scar tissue around the implant—was recorded in 37.2% of overseas revisions and 38.9% of domestic revisions. Most operations in both groups took place privately. Public hospitals handled 2.7% and 1.5%, respectively; those percentages describe where revisions occurred, not the full financial cost of care.

The missing denominator

The registry does not provide the total number of Australian residents who received implants abroad, including those who never needed a revision. It therefore cannot establish that an overseas recipient was more likely to need another operation, or quantify how much more likely. The comparison was observational and unadjusted, with differences in age and device characteristics. Provider credentials, patient-reported long-term outcomes and time from implantation to revision were not resolved by this analysis.

Nor does an implant placed overseas necessarily identify a trip undertaken for surgery. As the authors acknowledge, migration can explain some cases. Country rankings here would confuse the origin of recorded revised devices with the safety of all surgery in those countries.

Planning beyond the initial result

The US Food and Drug Administration's existing patient information explains that implants are not lifetime devices and describes the device card containing identifying details. This is longstanding background guidance, not a new warning prompted by the Australian study. It makes the relevant decision broader than an initial price or preferred size: ongoing care and accessible implant information also belong in the discussion.

The study does not show that a particular follow-up plan prevents revision. Its contribution is to describe the work that may arise after an initial cosmetic operation and the limits of the available records. For decisions across borders, a clear account of who will provide later care matters even when no reliable comparative risk figure is available.